Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda.

Bartelink IH, Savic RM, Mwesigwa J, Achan J, Clark T, Plenty A, Charlebois E, Kamya M, Young SL, Gandhi M, Havlir D, Cohan D, Aweeka F.

J Clin Pharmacol. 2014 Feb;54(2):121-32. doi: 10.1002/jcph.167. Epub 2013 Sep 21.

2.

The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.

Bartelink IH, Savic RM, Dorsey G, Ruel T, Gingrich D, Scherpbier HJ, Capparelli E, Jullien V, Young SL, Achan J, Plenty A, Charlebois E, Kamya M, Havlir D, Aweeka F.

Pediatr Infect Dis J. 2015 Mar;34(3):e63-70. doi: 10.1097/INF.0000000000000603.

3.

Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding.

Gandhi M, Mwesigwa J, Aweeka F, Plenty A, Charlebois E, Ruel TD, Huang Y, Clark T, Ades V, Natureeba P, Luwedde FA, Achan J, Kamya MR, Havlir DV, Cohan D; Prevention of Malaria and HIV disease in Tororo (PROMOTE) study.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):578-84. doi: 10.1097/QAI.0b013e31829c48ad.

4.

Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.

Cohan D, Natureeba P, Koss CA, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Gandhi M, Clark TD, Nzarubara B, Achan J, Ruel T, Kamya MR, Havlir DV.

AIDS. 2015 Jan 14;29(2):183-91. doi: 10.1097/QAD.0000000000000531.

5.

Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.

Koss CA, Natureeba P, Mwesigwa J, Cohan D, Nzarubara B, Bacchetti P, Horng H, Clark TD, Plenty A, Ruel TD, Achan J, Charlebois ED, Kamya MR, Havlir DV, Gandhi M.

AIDS. 2015 Apr 24;29(7):825-30. doi: 10.1097/QAD.0000000000000619. Erratum in: AIDS. 2015 Nov;29(17):2369.

6.

Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.

Koss CA, Natureeba P, Plenty A, Luwedde F, Mwesigwa J, Ades V, Charlebois ED, Clark TD, Achan J, Ruel T, Nzarubara B, Kamya MR, Havlir DV, Cohan D.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):128-35. doi: 10.1097/QAI.0000000000000281.

7.

Population pharmacokinetics of lopinavir/ritonavir (Kaletra) in HIV-infected patients.

López Aspiroz E, Santos Buelga D, Cabrera Figueroa S, López Galera RM, Ribera Pascuet E, Domínguez-Gil Hurlé A, García Sánchez MJ.

Ther Drug Monit. 2011 Oct;33(5):573-82. doi: 10.1097/FTD.0b013e31822d578b.

PMID:
21912331
8.

Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines.

Patterson KB, Dumond JB, Prince HA, Jenkins AJ, Scarsi KK, Wang R, Malone S, Hudgens MG, Kashuba AD.

J Acquir Immune Defic Syndr. 2013 May 1;63(1):51-8. doi: 10.1097/QAI.0b013e31827fd47e.

9.

Steady-state pharmacokinetics of lopinavir/ritonavir in combination with efavirenz in human immunodeficiency virus-infected pediatric patients.

King JR, Acosta EP, Yogev R, Wiznia A, Kraimer J, Graham B, Carey V, Britto P, Jean-Philippe P, Moye J, Watson D.

Pediatr Infect Dis J. 2009 Feb;28(2):159-61. doi: 10.1097/INF.0b013e3181861d8b.

10.

Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women.

Vieira CS, Bahamondes MV, de Souza RM, Brito MB, Rocha Prandini TR, Amaral E, Bahamondes L, Duarte G, Quintana SM, Scaranari C, Ferriani RA.

J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):378-85. doi: 10.1097/QAI.0000000000000189.

PMID:
24798768
11.

Reduced lopinavir exposure during pregnancy.

Stek AM, Mirochnick M, Capparelli E, Best BM, Hu C, Burchett SK, Elgie C, Holland DT, Smith E, Tuomala R, Cotter A, Read JS.

AIDS. 2006 Oct 3;20(15):1931-9.

PMID:
16988514
12.

Reduced indinavir exposure during pregnancy.

Cressey TR, Best BM, Achalapong J, Stek A, Wang J, Chotivanich N, Yuthavisuthi P, Suriyachai P, Prommas S, Shapiro DE, Watts DH, Smith E, Capparelli E, Kreitchmann R, Mirochnick M; IMPAACT P1026s team.

Br J Clin Pharmacol. 2013 Sep;76(3):475-83. doi: 10.1111/bcp.12078.

13.

Steady-state pharmacokinetics of lopinavir plus ritonavir when administered under different meal conditions in HIV-infected Ugandan adults.

Lamorde M, Byakika-Kibwika P, Boffito M, Nabukeera L, Mayito J, Ogwal-Okeng J, Tjia J, Back D, Khoo S, Ryan M, Merry C.

J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):295-8. doi: 10.1097/QAI.0b013e3182567a35.

14.

Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy.

López Aspiroz E, Cabrera Figueroa SE, Porras Hurtado GL, Cruz Guerrero R, Domínguez-Gil Hurlé A, Carracedo A; Tormes Team.

Curr Drug Metab. 2013 Sep;14(7):729-37.

PMID:
24001122
15.

No Need for Lopinavir Dose Adjustment during Pregnancy: a Population Pharmacokinetic and Exposure-Response Analysis in Pregnant and Nonpregnant HIV-Infected Subjects.

Salem AH, Jones AK, Santini-Oliveira M, Taylor GP, Patterson KB, Nilius AM, Klein CE.

Antimicrob Agents Chemother. 2015 Nov 2;60(1):400-8. doi: 10.1128/AAC.01197-15.

16.

Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers.

Calderón MM, Chairez CL, Gordon LA, Alfaro RM, Kovacs JA, Penzak SR.

Pharmacotherapy. 2014 Nov;34(11):1151-8. doi: 10.1002/phar.1473. Epub 2014 Aug 20.

17.

The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis.

Gupta SK, Rosenkranz SL, Cramer YS, Koletar SL, Szczech LA, Amorosa V, Hall SD.

AIDS. 2008 Oct 1;22(15):1919-27. doi: 10.1097/QAD.0b013e32830e011f.

18.

Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients.

Ma Q, Vaida F, Wong J, Sanders CA, Kao YT, Croteau D, Clifford DB, Collier AC, Gelman BB, Marra CM, McArthur JC, Morgello S, Simpson DM, Heaton RK, Grant I, Letendre SL; CHARTER Group.

J Neurovirol. 2016 Apr;22(2):170-8. doi: 10.1007/s13365-015-0382-7. Epub 2015 Sep 25.

19.

Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands.

Bastiaans DE, Forcat S, Lyall H, Cressey TR, Hansudewechakul R, Kanjanavanit S, Noguera-Julian A, Königs C, Inshaw JR, Chalermpantmetagul S, Saïdi Y, Compagnucci A, Harper LM, Giaquinto C, Colbers AP, Burger DM; PENTA 18KONCERT Study Group.

Pediatr Infect Dis J. 2014 Mar;33(3):301-5. doi: 10.1097/INF.0000000000000014.

PMID:
24356253
20.

Lopinavir/ritonavir-based antiretroviral treatment (ART) versus efavirenz-based ART for the prevention of malaria among HIV-infected pregnant women.

Natureeba P, Ades V, Luwedde F, Mwesigwa J, Plenty A, Okong P, Charlebois ED, Clark TD, Nzarubara B, Havlir DV, Achan J, Kamya MR, Cohan D, Dorsey G.

J Infect Dis. 2014 Dec 15;210(12):1938-45. doi: 10.1093/infdis/jiu346. Epub 2014 Jun 23.

Supplemental Content

Support Center